Ertapenem's therapeutic potential for Mycobacterium avium lung disease in the hollow fibre model.

Devyani DeshpandeShashikant SrivastavaTawanda Gumbo

Published in: International journal of antimicrobial agents (2024)

Ertapenem microbial kill below day 0 burden was better than guideline-based therapy drugs in the HFS-MAC in the past. Ertapenem is a promising drug for novel combination therapies for MAC lung disease.

Keyphrases

mycobacterium tuberculosis
microbial community
drug induced
emergency department
adverse drug
replacement therapy